Hepatitis A Vaccine Should Work for 30 Years

A recent study (PR Spradling et al. Hepatology 2016; 63: 703-11) provided data indicating that the Hepatitis A virus (HAV) vaccine would likely work for 30 years after childhood vaccination.  Much has changed since the implementation of the HAV vaccine.  Since 2000, the number of HAV case in the U.S. has dropped almost 90%, from 13,397 to 1781 in 2013 with the lowest incidence in those ≤18 years.

This study (n=183) examined three groups of Alaska Native children who received a two-dose inactivated HAV vaccine.

  • Vaccine starting at age 6 months (group 1)
  • Vaccine starting at age 12 months (group 2)
  • Vaccine starting at age 15 months (group 3)

Key findings:

  • All participants in groups 2 and 3 through age 10 years were seropositive (anti-HAV ≥ 20 mIU/mL), whereas in group 1 it was >90%.
  • At 15-16 years following vaccination, the seropositivity was 50-75% in group 1 and 67-87% in groups 2 and 3.
  • Using modeling, the overall 30-year anti-HAV seropositivity was predicted to be present in 64% of all participants and 84% of those that were seropositive at 15-16 years.

HAV continues to represent an ongoing threat, despite a reduction in the number of cases.  This is particularly due to unvaccinated travelers and unvaccinated adutls.  In vaccinated adults, a study (Vaccine 2015; 33: 5723-27) inidcates that seropositivity would be present in at least 95% after 30 years and 90% after 40 years.

My take: these data provide reassurance that HAV vaccine’s protection will be durable among those who were vaccinated between 6-21 months of life.

Related blog posts:

Culebra, Puerto Rico

Culebra, Puerto Rico

“The Couric Effect”

A recent commentary (Am J Gastroenterol advance online publication 29 March 2016; doi: 10.1038/ajg.2016.118) by Katie Couric provides a summary of her personal journey as an advocate for preventing colon cancer.

A good read: An Unexpected Turn: My Life as a Cancer Advocate

Here’s an excerpt:

“April is the cruelest month,” T.S. Eliot wrote in “The Waste Land,” and in 1997 it certainly was for my family. That’s when my husband Jay and I discovered he had stage IV colon cancer that had spread to his liver…and the beginning of a 9-month nightmare…

the University of Michigan found that my televised colonoscopy and educational outreach contributed to a sustained 19% increase in the number of colonoscopies performed nationwide. They called it “The Couric Effect”

Screen Shot 2016-03-29 at 4.59.42 PM

Fresh Fruit Study

A study from China has shown benefits associated with increased fresh fruit intake (H Du et al. NEJM; 2016; 374: 1332-43). Abstract Link: Fresh Fruit Consumption and Major Cardiovascular Disease in China

Study methods: 512,891 adults recruited from 2004-2008.  Prospective cohort.

Results: 18% of participants consumed fresh fruit daily.  This group had lower systolic blood pressure (by 4 mm Hg), lower glucose (by 0.5 mmol/L) (both with P<0.001).  The adjusted hazard ratio for cardiovascular death was 0.6 (CI 0.54-0.67), 0.66 for major coronary event, 0.75 for ischemic stroke, and 0.64 for hemorrhagic stroke.

Limitation: Fruit consumption was correlated with socioeconomic status and this may have affected findings even after adjustment due to residual confounding.

My take: While fruit consumption has not been proven to cause better health, daily fruit consumption is associated with better outcomes.

Related blog postEat your veggies…if you don’t want to get sick | gutsandgrowth

Savings with veggies

 

Looking for Value in Medicine

  • Finding Value in Unexpected Places — Fixing the Medicare Physician Fee Schedule.  RA Berenson, JD Goodson. NEJM 2016; 374: 1306-10.
  • When Is It Ethical to Withhold Prevention? TA Farley.  NEJM 2016; 374: 1303-5.

As noted in yesterday’s blog post, after reading these two commentaries I thought a little more about value in pediatric gastroenterology.  These articles though focus on other aspects.  In the first reference, the authors explain the flaws with moving from volume to value-based care.  They note that the medicare physician fee schedule (MPFS) has a powerful influence on physician activities and “their tendency to perform unneeded tests and procedures.”  In fact, the fee schedule heavily contributes to growing shortages of primary care physicians.  Key points:

  • “Two key flaws in the RBVS [resource-based relative value scale] are its substantial misevaluations of physician work and the failure of current service codes to capture the range and intensity of nonprocedural physician activities, known as evaluation and management (E/M) services.”
  • “The MPFS still assumes that it takes nearly 30 minutes to interpret a magnetic resonance image of the brain…typically takes about 10.”  Echocardiogram per MPFS assumes 31 minutes, but takes 5-10 minutes.  For colonoscopy with polyp removal, MPFS assumes 78 minutes, but this is overestimated as well.
  • Valuations depend on AMA-sponsored expert panels…not surprisingly, updates that reduce RVUs are rarely proposed.
  • While the commentary implies that procedural codes are overvalued, it notes that due to complexity of chronic conditions that E/M codes are undervalued.
  • Their conclusion: “implementing new incentives and quality measures in new payment models while maintaining a broken fee schedule is a prescription for failure.”

The second reference bemoans the fact that the medical system will spend enormous amounts of money to prolong the life of an individual with terminal cancer for a few weeks but will not see the imperative of providing adequate prevention measures. Key points:

  • “Many people reject any attempt to put a dollar value on human life…but…limits of funding make it impossible to pay for every conceivable intervention.”
  • Cost-effectiveness is not considered by Medicare in determining treatment.  “For example, treatment of metastatic lung cancer may cost $800,000 per QALY [quality-adjusted life-year], but it is typically provided.  In sharp contrast, primary preventative services are often withheld even if they are highly cost-effective.”
  • Diabetes prevention program focused on exercise and nutrition has QALY costs of $14,000.  Smoking cessation with nicotine-replacement therapy has QALY <$5000.
  • Author’s conclusion: “because withholding primary prevention leads to unnecessary suffering and death, we should be just as creative in finding ways to pay for it” as we do with treatment of all illnesses.

My take: At an individual physician level, we need to keep working to utilize our resources more carefully.  However, at a policy making level, efforts at improving incentives for primary prevention and primary care are needed.

Related blog posts (see yesterday’s post Why are so many Low Value Endoscopies Performed? for related links as well):

Poster on Front of High Museum is reproduction of Vik Muniz piece created from Jelly and Peanut Butter

Poster on Front of High Museum is reproduction of Vik Muniz piece created from Jelly and Peanut Butter

 

Why Are So Many “Low Value” Endoscopies Performed?

After reading a few commentaries regarding value in medicine (which I will summarize tomorrow), it made me think a little more about value in pediatric gastroenterology.

I recently observed that a pediatric gastroenterologist in another group had a pattern of scheduling a lot of procedures.  In pediatric gastroenterology, we are not doing endoscopies to screen for malignancy.  The majority of children evaluated in our offices do not have organic disease.  In addition, there are a number of variables that can be used to select patients who are most likely to benefit from evaluation. In fact, much of our value comes from this selection process, because non-physicians can be taught to be endoscopic technicians.

My reaction to this volume of cases was that I thought either this practitioner was seeing a ton of patients, had been away and had accumulated a number of cases, or that this was low value care.  Though, another possibility is that the physician may be influenced by the “illusion of control” or “therapeutic illusion.” (NEJM full text: The Science of Choosing Wisely –Overcoming the Therapeutic Illusion).  According to a recent editorial, “When physicians believe that their actions or tools are more effective than they actually are, the results can be unnecessary and costly care.”

“The therapeutic illusion is reinforced by a tendency to look selectively for evidence of impact — one manifestation of the “confirmation bias” that leads us to seek only evidence that supports what we already believe to be true.”

Whatever the circumstances with regard to endoscopy volume, my intent is not to single out an individual or specific group.  My impression is that there are a lot more pediatric endoscopies being done these days and many are not needed.  While I recognize that clinicians recommend endoscopy with a great deal of variation, my suspicion is that those who use endoscopy less frequently are likely to see similar outcomes.  So, why are there so many low value endoscopies performed?

  1. The entire system is incentivized to do more procedures.  Physicians and hospitals are compensated more for doing these procedures.
  2. Families and sometimes referring physicians think these procedures are necessary.  In fact, there are studies that generally indicate higher levels of patient satisfaction when more diagnostic tests are done even if they are unnecessary.
  3. Physicians have a great deal of knowledge asymmetry in healthcare compared with families and it is expected that they will use their knowledge to help families pursue appropriate care.  While all physicians may have some lapses, some physicians skirt this part of their job.  One physician described this type of pediatric GI practice to me: “Scope first, think second.”

This blog has highlighted numerous aspects of health care economics.  Pharmaceutical companies and hospitals have been criticized for gaming the system.  The blog has discussed efforts to improve value like the “Choosing Wisely” campaign.  Though, it is interesting to note that even with this campaign, most physician groups rarely identified areas that would affect their financial bottom-line.  Among pediatric gastroenterologists, a frequent concern that I hear regards the overuse of CT scans by emergency room physicians.

When I take my car for repairs, I don’t want them doing an expensive overhaul unless it is really needed.  If a car needs a muffler change, but the repairman recommended a few thousand dollars of repairs, that would be outrageous.  Yet, in many cases with children, who are more precious than cars, the main difference with excessive endoscopic procedures, is that health insurance covers the majority of the costs.

I wonder too whether the frequency of endoscopy procedures actually discourages some families from having endoscopic procedures when they are clearly needed (eg. suspected celiac disease, suspected inflammatory bowel disease).

My take: Financial resources are limited.  When physicians do not help utilize resources well, this results in poor care, whether families realize this or not.  Ultimately, this will result in increased regulatory burdens for all physicians to more carefully justify what they are doing and/or result in efforts to eliminate financial incentives for unnecessary care.  However, as noted previously (Do deductibles work to improve smart spending on health care?), financial incentives often affect both low value and high value care.

Any readers care to comment?

Related blog posts:

ViK Muniz Art -done completely from chocolate syrup

ViK Muniz Art -done completely from chocolate syrup -see the picture below for comparison.

The Vik Muniz piece is modeled after this photograph of Jackson Pollack

The Vik Muniz piece above is modeled after this photograph of Jackson Pollack

Drug-Induced Liver and Skin Reactions

A recent study (H Devarbhavi et al. Hepatology 2016; 63: 993-99 & associated editorial 700–2) provide insight into outcomes and causative agents in patients who had both drug-induced liver injury (DILI) along with severe skin reactions.

With regard to the skin reactions, the authors were specifically focused on Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  SJS indicates an area of skin detachment of <10% and TEN involves >30%.  SJS/TEN overlap is 10-30%.

The study reviewed a single center DILI registry over 18 years with 748 patients.  There was prospective recruitment during the final 10 years of the study period (1997-2015). 36 (4.8%) had either SJS or TEN (mean age 32 years, 53% females).  9/36 (25%) were <18 years.

Causative agents:

  • Antiepileptics 47%
  • Sulfonamides 18%
  • Nevirapine 16%
  • Multiple agents 61%

Key points:

  • Median duration between drug initiation and onset of rash was 24 days
  • 13/36 (36%) died. 77% of those who died had jaundice.
  • 14/36 (39%) received steroids including 10 survivors and 4 who died.

While a mortality of 36% among those with both DILI and SJS/TEN is high, the discussion notes that the mortality is high even in those without DILI (~18% in ones study).  There were 8/36 in the study with HIV which is associated with a much higher risk of DILI.  There was a lower mortality in the pediatric age group (1 child 11%) and in those with HIV (1 patient 12.5%).

Related blog posts:

Walnut Street Bridge

Walnut Street Bridge

Persistent Symptoms after Lyme Disease

A new study has shown that long-term antibiotic therapy for Lyme disease is not helpful.

Here’s a link to a quick summary (1:37 min): Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease

In the associated editorial (MT Melia, PG Auwaeter, NEJM 2016; 374: 1277-8), it is noted that 10-20% of treated patients (after initial antibiotics) “may have lingering symptoms of fatigue, musculoskeletal pains…The plausible idea that additional antimicrobial therapy for potentially persistent bacterial infection would foster improvement has been a touchstone of hope in the 40 years since discovery of the disease in the mid-1970s.”

My take (from editorial): “Prolonged antibiotic therapy is not the answer” for lingering symptoms after Lyme disease. “We do not know what is truly helpful”

Related blog post: Facts and fiction with Lyme disease gutsandgrowth

 

Screen Shot 2016-03-31 at 6.33.43 PM

Liver Transplant Recipients Are Getting Older

Data(F Su et. al. Gastroenterol 2016; 150: 441-53) from 2002 thru 2014 indicate that liver transplant recipients are getting older.

The researchers reviewed data from the United Network for Organ Sharing (UNOS), including 60,820 adults who underwent liver transplantation and 122,606 listed for transplantation. Key findings:

  • Mean age of those listed increased from 51.2 to 55.7 years.  This trend was more prominent among those with hepatitis C (50.9 –>57.9).
  • The proportion of listed patients ≥60 years increased from 19% to 41%.
  • There were no differences in 5-year transplant-related survival “benefit”

The topic of survival “benefit” is reviewed in the discussion and the associated editorial (pg 306).  The survival benefit is calculated as the difference between life expectancy with and without liver transplantation. So, even though older transplant recipients have worse post-transplantation survival, this is counterbalance by the increased risk of waitlist mortality.  It is quite likely, however, that with more time (>5 year followup) that the survival benefit for younger patients would be more apparent.  In addition, the idea that the survival benefit could be equivalent could be influenced by selection bias.  Many transplant centers may be more selective when deciding to place older patients (>70 years) on the waitlist.

My take: The steady increase in age in adult liver transplant recipients is a concern due to worse outcomes in older patients.  This trend could be reversed if hepatitis C becomes a less frequent indication for liver transplantation.

Related blog posts:

Best Way to Quit Smoking

According to a recent study (N Lindson-Hawley et al.
Ann Intern Med. Published online 15 March 2016 doi:10.7326/M14-2805), for patients interested in quitting smoking, the best way is to do this abruptly rather than gradually (25% more successful).  Apparently, the gradual approach adds work to the process.

From Abstract:

Results: At 4 weeks, 39.2% (95% CI, 34.0% to 44.4%) of the participants in the gradual-cessation group were abstinent compared with 49.0% (CI, 43.8% to 54.2%) in the abrupt-cessation group (relative risk, 0.80 [CI, 0.66 to 0.93]). At 6 months, 15.5% (CI, 12.0% to 19.7%) of the participants in the gradual-cessation group were abstinent compared with 22.0% (CI, 18.0% to 26.6%) in the abrupt-cessation group (relative risk, 0.71 [CI, 0.46 to 0.91]). Participants who preferred gradual cessation were significantly less likely to be abstinent at 4 weeks than those who preferred abrupt cessation (38.3% vs 52.2%; P = 0.007).

Here’s a link to a 4 minute summary: Gradual versus Abrupt Smoking Cessation

Related blog posts:

Gibbs Gardens

Gibbs Gardens